MedTrace Logo

Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers

NCT02117245 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2015-01-08

No results posted yet for this study

Summary

The objective of this study is to assess the bioavailability of the MGCD265 formulation following oral administration under fed conditions (Treatment-1) as compared to fasting conditions (Treatment-2) in healthy male and female volunteers.

Conditions

  • Healthy

Sponsors & Collaborators

  • Mirati Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Manuela Juretic · MethylGene Inc.

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2012-10-31
Completion
2012-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02117245 on ClinicalTrials.gov